Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis has obtained encouraging preliminary results from two large prospective trials, evaluating the safety and efficacy of regimens based on Eloxatin and Genetech's Avastin in metastatic colorectal cancer.
Subscribe to our email newsletter
TREE-2 is the first study to assess the safety of Eloxatin-based regimens combined with Genentech’s Avastin (bevacizumab) for the first-line treatment of metastatic colorectal cancer. Preliminary efficacy results suggested that adding bevacizumab improved the response rate of all Eloxatin-based regimens.
Researchers from the Eastern Cooperative Oncology Group (ECOG) also reported results of the E3200 study, which demonstrated a significant 26% reduction in the risk of death for patients receiving Eloxatin-based chemotherapy (FOLFOX4) plus bevacizumab, compared to those who received FOLFOX4 alone.
Although patients in the E3200 study had previously been treated for advanced or metastatic colorectal cancer, median overall survival with Eloxatin-based chemotherapy plus bevacizumab was 12.5 months compared to 10.7 months with FOLFOX4 alone.
Eloxatin was developed in association with Debiopharm SA and is currently marketed by Sanofi-Aventis in more than 60 countries.
Bevacizumab is manufactured by Genentech, co-developed with Roche, and is used with intravenous 5-FU-based chemotherapy in the first-line treatment of patients with metastatic cancer of the colon or rectum.